Claims for Patent: 6,280,951
✉ Email this page to a colleague
Summary for Patent: 6,280,951
Title: | Method for prediction of PTH reactivity by polymorphism of PTHR gene |
Abstract: | A method for predicting reactivity to parathyroid hormone by determining the genotype with respect to polymorphism in the parathyroid hormone receptor gene. The results obtained by the analysis of genetic polymophism are useful for predicting the tendency for a hemodialyzed patient to develop severe secondary hyperparathyroidism, or for predicting the tendency for a human individual to develop severe primary hyperparathyroidism. Also, this method is useful for predicting the therapeutic effects by predicting reactivity to parathyroid hormone in a patient who is being treated for regressive osteoporosis by administration of parathyroid hormone. |
Inventor(s): | Heishi; Masayuki (Sagamihara, JP), Ishida; Osamu (Sagamihara, JP), Tazawa; Hiromitsu (Sagamihara, JP), Tsukamoto; Yusuke (Kanagawa, JP) |
Assignee: | Tsukamoto; Yusuke (Yokohama, JP) Sumikin Bio-Science, Inc. (Sagamihara, JP) |
Application Number: | 09/521,656 |
Patent Claims: | 1. A method for predicting reactivity to parathyroid hormone in a human, comprising determining a genotype in the parathyroid hormone receptor gene with respect to Van91 I
polymorphism, thereby predicting the reactivity to parathyroid hormone, wherein detection of the VV or Vv genotype in the parathyroid hormone receptor gene with respect to the Van91 I polymorphism indicates an increase in PTH reactivity relative to the
vv genotype.
2. The method according to claim 1, wherein the genotype is determined by amplifying the first intron region of the parathyroid hormone receptor gene and treating the amplified DNA fragment with restriction enzyme Van91 I to obtain the digestion pattern. 3. The method according to claim 2, wherein the amplification is carried out using a primer having the sequence of SEQ ID NO:1 and a primer having the sequence of SEQ ID NO:2. 4. A primer set for use in analyzing the Van91 I polymorphism in the parathyroid hormone receptor gene, consisting of a primer having the sequence of SEQ ID NO:1 and a primer having the sequence of SEQ ID NO:2. 5. A kit for use in predicting reactivity to parathyroid hormone in a human, comprising the primer set according to claim 4 and restriction enzyme Van91I. 6. A method for predicting reactivity to parathyroid hormone in a patient who is being treated for regressive osteoporosis by administration of parathyroid horme, comprising determining a genotype in the parathyroid hormone receptor gene with respect to Van91 I polymorphism, thereby predicting the reactivity to parathyroid hormone. 7. The method according to claim 6, wherein the genotype is determined by amplifying the first intron region of the parathyroid hormone receptor gene and treating the amplified DNA fragment with restriction enzyme Van91 I to obtain the digestion pattern. |
Details for Patent 6,280,951
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2019-03-09 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2019-03-09 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2019-03-09 | |
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2019-03-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.